Approval success rates highlight the superiority of therapeutic antibodies in clinical trials over conventional drug candidates. The TGN1412-HV clinical trial re-ignited discussion on critical translation factors for therapeutic antibody candidates.

To access this article, please click on your left "Subscription". Thank you.